Publication date: Jul 17, 2025
Nanobodies, derived from the immune systems of camelids such as alpacas and llamas, represent a novel class of therapeutics with significant potential in fighting respiratory viral infections, such as SARS-CoV-2 and influenza. Nanobodies are small biomolecules that are highly stable and have unique binding features that allow for the effective neutralization of viral particles and inhibition of viral replication. This review highlights the advantages of nanobodies over traditional antibodies, including cost-effective production and enhanced specificity for target antigens. We discuss the mechanisms through which nanobodies block viral entry, their applications in diagnostics, and the methodologies for their development, such as phage display technology. Furthermore, we explore the efficacy of nanobodies in preclinical studies and their potential in clinical settings. As research progresses, structural optimization and the exploration of combination therapies may enhance their therapeutic efficacy, providing a promising approach for addressing global health challenges caused by emerging viral pathogens.
| Concepts | Keywords |
|---|---|
| Biomolecules | antibodies |
| Camelids | Nanobodies |
| Fighting | phage display technology |
| Influenza | SARS-COV-2 |
| Promising | VHH domain |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | viral infections |
| disease | MESH | influenza |
| disease | IDO | production |